



Figure S1 Study selection flow chart. SCLC, small cell lung cancer; HRQoL, health-related quality of life; RCT, randomised controlled trial.

Table S1 Summary of 14 published randomized IM trials (16 treatment comparisons) in stage III/IV NSCLC

Trial	Treatment	Control	Histology	Stage	Pre treated	Primary endpoints	Primary population
Antonia <i>et al.</i> , 2017	durvalumab	placebo	NSCLC	3	Y	OS + PFS	All comers
Barlesi <i>et al.</i> , 2018	avelumab	docetaxel	NSCLC	3b/4/r	Y	OS	PD-L1 \geq 1%
Borghaei <i>et al.</i> , 2015	nivolumab	docetaxel	Nonsquamous	3b/4/r	Y	OS	All comers
Brahmer <i>et al.</i> , 2015	nivolumab	docetaxel	Squamous	3b/4	Y	OS	All comers
Carbone <i>et al.</i> , 2017	nivolumab	plat-based chemo	NSCLC	4/r	N	PFS	PD-L1 \geq 5%
Fehrenbacher <i>et al.</i> , 2016	atezolizumab	docetaxel	NSCLC	3b/4/r	Y	OS	All comers
Gandhi <i>et al.</i> , 2018	Pembrolizumab + plat-based chemo	Placebo + plat-based chemo	Nonsquamous	4	N	OS + PFS	All comers
Govindan <i>et al.</i> , 2017	Ipilimumab + CP	Placebo + CP	Squamous	4/r	N	OS	All comers
Herbst <i>et al.</i> , 2016, 10 mg	pembrolizumab 10 mg/kg	docetaxel	NSCLC	3b/4/r	Y	OS + PFS	PD-L1 \geq 1%
Herbst <i>et al.</i> , 2016, 2 mg	pembrolizumab 2 mg/kg	docetaxel	NSCLC	3b/4/r	Y	OS + PFS	PD-L1 \geq 1%
Langer <i>et al.</i> , 2016	Pembrolizumab + car + peme	Car + peme	Nonsquamous	3b/4	N	OR	All comers
Lynch <i>et al.</i> , 2012, A	phased ipilimumab + CP	Placebo + CP	NSCLC	3b/4	N	irPFS	All comers
Lynch <i>et al.</i> , 2012, B	concurrent ipilimumab + CP	Placebo + CP	NSCLC	3b/4	N	irPFS	All comers
Reck <i>et al.</i> , 2016	pembrolizumab	plat-based chemo	NSCLC	4	N	PFS	PD-L1 \geq 50%
Rittmeyer <i>et al.</i> , 2017	atezolizumab	docetaxel	NSCLC	3b/4	Y	OS	All comers
Socinski <i>et al.</i> , 2018	Atezolizumab + CP	Bevacizumab + CP	Nonsquamous	4/r	Y + N	OS + PFS	All comers

NSCLC, non-small cell lung cancer; Pre, Previously; OS, overall survival; PFS, progression-free survival; Ep, end point; Popu, population; Pub, publish; pac, paclitaxel; car, carboplatin; peme, pemetrexed; plat, platinum; chemo, chemotherapy; nons, nonsquamous; CP, carboplatin + paclitaxel.